Cancer – AALL1732: A Phase 2 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Condition or Therapy:
Cancer and Blood Disorders
Study Number: AALL1732
What is the goal of this study?
The goal of this study is to determine, in a randomized manner, if the addition of 2 blocks of inotuzumab ozogamicin to modified Berlin-Frankfurt-Münster (mBFM) chemotherapy will improve 5-year disease-free survival (DFS) in children and young adults with High-Risk (HR) B-cell acute lymphoblastic leukemia (B-ALL).
Who can join the study?
This study may be a good fit for children and young adults who:
- Are between 1 and 24 years old
- Patients with B-ALL meet one of the follwing white blood count (WBC) criteria:
- Age 1 - 9.99 years: WBC >= 50,000/uL
- Age 10 - 24.99 years: Any WBC
- Age 1 - 9.99 years: WBC < 50,000/UL with
- Testicular leukemia
- CNS lukemia (CNS3)
- Steriod pretreatment
- Are newly diagnosed with B-ALL or MPAL (by WHO2016 criteria) with > 25% blasts on a bone marrow (BM) aspirate
What will happen if my child takes part in this study?
You can read more about this study on clinicaltrials.gov.
Who can I contact for more information?
To learn more, call 206-987-2106 or email the study coordinator.